⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2025

Supplementary Figure 5 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4⁺ T Cells

Signe Caksa Timothy J. Purwin Dan A. Erkes Kristen M. DeRosa Erica Kitterman Samantha M. Barnada Casey D. Stefanski Haley P. Wilson Glenn L. Mersky McKenna Q. Glasheen Jacob S. Heilizer Namra Ajmal Yunguang Sun Joanna Chan Hallgeir Rui Inna Chervoneva Claudia Capparelli Andrew E. Aplin

View Full Paper

Ask AI

Bookmark

Share

Key Points

Knockdown of transglutaminase-2 does not alter therapy response in SOX10-deficient melanoma, indicating neutral effects on treatment outcomes.
The study reveals decreased intratumoral CD4 T cells when transglutaminase-2 is elevated, emphasizing its role in immune evasion.
SOX10-deficiency leads to increased tumor onset and progression, connecting genetic factors with immune cell dynamics in melanoma.
The findings may highlight new therapeutic targets in managing immune response in melanoma patients with specific genetic alterations.

Implication

Knockdown of transglutaminase-2 did not alter targeted therapy response in SOX10-deficient melanoma, suggesting potential immune interactions.

Abstract

TGM2 knockdown does not affect response to targeted therapy in SOX10-deficient melanoma

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Caksa et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21978 https://doi.org/10.1158/0008-5472.30255551

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4<sup>+</sup> T Cells2025
2Supplementary Figure 1 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4<sup>+</sup> T Cells2025
3Supplementary Figure 6 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4<sup>+</sup> T Cells2025
4Supplementary Figure 3 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4<sup>+</sup> T Cells2025
5Supplementary Figure 7 from Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4<sup>+</sup> T Cells2025